Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Haige Chen, Xinan Sheng, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyan Liu, Jin WU, Fangjian Zhou, Zhisong He, Jinhai Fan, Yiran Huang, Jun Guo, Shanghai Junshi Biosciences
Institutions: Shanghai Jiao Tong University, Renji Hospital, Peking University Cancer Hospital, Liaoning Cancer Hospital & Institute, Tongji University, Tianjin Medical University Cancer Institute and Hospital, Shanghai Tenth People's Hospital, First Hospital of Jilin University, Nanjing Drum Tower Hospital, Chinese PLA General Hospital, Chinese People's Liberation Army, Peking Union Medical College Hospital, Chongqing University, Chongqing Cancer Hospital, Qilu Hospital of Shandong University, Sichuan University, West China Hospital of Sichuan University, Harbin Medical University, Sun Yat-sen University Cancer Center, Peking University, Peking University First Hospital, First Affiliated Hospital of Xi'an Jiaotong University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298902